Trial reportJournal of cosmetic dermatology2026
Effectiveness and Safety of Recombinant Type III Humanized Collagen Solution Injection Combined With Collagen-III Multi-Peptide Serum in Improving Signs of Photoaging: A Prospective, Split-Face Controlled Clinical Trial.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSkin aging is a multifactorial process involving the progressive deterioration of skin structure and function, marked by collagen degeneration, impairing the structural integrity of the dermis. Intradermal injection of recombinant type III humanized collagen (RhCol-III) solution is a promising anti-aging strategy through direct collagen replenishment, but its synergistic effects when combined with a collagen-III multi-peptide serum remain unexplored.
aimsThis study evaluates the effectiveness and safety of a RhCol-III solution injection combined with a collagen-III multi-peptide serum in improving photoaging.
methodsA prospective, single-center, randomized, split-face, single-blind trial was conducted. Participants received an intradermal injection of 2 mg/mL RhCol-III solution with application of collagen-III multi-peptide serum on the test side and intradermal injection of RhCol-III solution only on the control side. The 12-week follow-up period assessed effectiveness and safety, with the primary endpoint being the participant-reported skin satisfaction score (FACE-Q satisfaction with skin) at 4 weeks post-treatment.
resultsA total of 54 participants were enrolled. The primary endpoint, FACE-Q skin satisfaction score at week 4, significantly improved on both tested and control sides by 40.0% vs. 34.8% from baseline (both p < 0.0001; p < 0.05 between sides). By week 12, the tested side showed significantly better outcomes versus the control side in FACE-Q skin satisfaction scores, GAIS significant improvement rates, improvement rates of fine lines and skin firmness (all p < 0.05). No adverse events related to the RhCol-III solution injection were observed.
conclusionsThe combination of injectable RhCol-III and topical collagen-III multi-peptide serum is effective and safe in ameliorating photoaging of the forehead, periorbital and cheek areas among the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.